https://www.nasdaq.com/press-release/annovis-bio-announces-official-unique-name-buntanetap-for-lead-candidate-anvs401-2022
https://www.nasdaq.com/press-release/annovis-bio-to-participate-in-the-biotech-showcase-and-h.c.-wainwright-bioconnect
https://www.nasdaq.com/press-release/annovis-bio-ceo-maria-maccecchini-issues-letter-to-stockholders-2021-12-20
https://www.nasdaq.com/press-release/annovis-bio-announces-publication-of-anvs401-mechanism-of-action-in-peer-reviewed
https://www.nasdaq.com/press-release/annovis-bio-announces-transfer-of-listing-to-the-new-york-stock-exchange-2021-11-15
https://www.nasdaq.com/press-release/annovis-bio-presented-at-the-14th-clinical-trials-on-alzheimers-disease-conference
https://www.nasdaq.com/press-release/annovis-bio-presents-poster-on-mechanism-of-action-at-the-14th-clinical-trials-on
https://www.nasdaq.com/press-release/annovis-bio-to-present-at-the-14th-clinical-trials-on-alzheimers-disease-ctad
https://www.nasdaq.com/press-release/annovis-bio-announces-positive-phase-2-efficacy-data-for-the-treatment-of-parkinsons
https://www.nasdaq.com/press-release/annovis-bio-to-present-at-the-cantor-global-healthcare-conference-2021-09-24
https://www.nasdaq.com/press-release/annovis-bio-to-present-at-the-h.c.-wainwright-23rd-annual-global-investment
https://www.nasdaq.com/press-release/annovis-bio-interview-to-air-on-bloomberg-u.s.-on-the-redchip-money-reportr-2021-09
https://www.nasdaq.com/press-release/annovis-bio-to-present-at-biomarkers-for-alzheimers-disease-summit-2021-2021-08-25
https://www.nasdaq.com/press-release/annovis-bio-completes-dosing-of-parkinsons-disease-patients-with-anvs401-in-phase-2a
https://www.nasdaq.com/press-release/annovis-bio-pleased-by-positive-interim-results-from-ongoing-phase-ii-clinical-trials
https://www.nasdaq.com/press-release/annovis-bio-presents-new-clinical-and-biomarker-data-at-2021-alzheimers-association
https://www.nasdaq.com/press-release/annovis-bio-to-present-new-data-at-2021-alzheimers-association-international
https://www.nasdaq.com/press-release/annovis-bio-to-present-at-2021-bio-digital-2021-06-10
https://www.nasdaq.com/press-release/annovis-bio-expands-potential-application-of-anvs401-to-infectious-diseases-with-new
https://www.nasdaq.com/press-release/annovis-bio-to-present-at-jefferies-virtual-healthcare-conference-2021-2021-06-03
https://www.nasdaq.com/press-release/annovis-bio-engages-global-executive-search-leader-spencer-stuart-to-expand-its-board
https://www.nasdaq.com/press-release/annovis-bio-inc.-announces-closing-of-%2450-million-public-offering-2021-05-27
https://www.nasdaq.com/press-release/annovis-bio-inc.-announces-pricing-of-public-offering-2021-05-23
https://www.nasdaq.com/press-release/annovis-bio-inc.-announces-proposed-public-offering-of-common-stock-2021-05-21
https://www.nasdaq.com/press-release/annovis-bio-announces-positive-phase-2-data-anvs401-improves-cognition-in-alzheimers
https://www.nasdaq.com/press-release/annovis-bio-to-participate-in-alzheimer-disease-panel-presented-by-maxim-group-llc
https://www.nasdaq.com/press-release/annovis-bio-announces-positive-phase-2-data%3a-anvs401-significantly-lowers
https://www.nasdaq.com/press-release/annovis-bio-appoints-accomplished-neuroscientist-dr.-cheng-fang-as-vp-of-research
https://www.nasdaq.com/press-release/annovis-bio-files-for-fda-orphan-drug-designation-for-anvs401-for-the-treatment-of
https://www.nasdaq.com/press-release/annovis-bio-to-participate-at-the-benzinga-global-small-cap-conference-and-present-to
https://www.nasdaq.com/press-release/annovis-bio-to-ring-closing-bell-at-the-new-york-stock-exchange-2021-05-13
https://www.nasdaq.com/press-release/annovis-bio-receives-us-patent-for-method-of-treating-frontotemporal-dementia-and
https://www.nasdaq.com/press-release/annovis-bio-to-study-potential-of-anvs401-to-normalize-brain-development-in-down
https://www.nasdaq.com/press-release/annovis-bio-appoints-reid-mccarthy-to-board-and-to-role-of-audit-committee-chairman
https://www.nasdaq.com/press-release/annovis-bio-presenting-at-m-vest-and-maxim-group-inaugural-emerging-growth-virtual
https://www.nasdaq.com/press-release/annovis-bio-announces-positive-phase-2-data-interim-data-shows-anvs401-improves-speed
https://www.nasdaq.com/press-release/annovis-bio-inc.-to-present-at-the-q1-virtual-investor-summit-2021-03-11
https://www.nasdaq.com/press-release/annovis-bio-signs-gmp-manufacturing-agreement-to-support-planned-late-stage-studies
https://www.nasdaq.com/press-release/annovis-bio-receives-japanese-patent-for-the-treatment-of-acute-brain-or-nerve-injury
https://www.nasdaq.com/press-release/annovis-bio-to-present-at-the-h.c.-wainwright-global-life-sciences-conference-2021-03
https://www.nasdaq.com/press-release/annovis-bio-to-present-at-the-bio-ceo-investor-digital-conference-2021-02-16
https://www.nasdaq.com/press-release/annovis-bio-receives-european-patent-for-method-of-treating-acute-nerve-and-brain
https://www.nasdaq.com/press-release/annovis-bios-lead-candidate-anvs401-improves-cognitive-and-functional-outcomes-in
https://www.nasdaq.com/press-release/annovis-bio-to-present-at-h.c.-wainwright-bioconnect-2021-conference-2021-01-05
https://www.nasdaq.com/press-release/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-1
https://www.nasdaq.com/press-release/annovis-bio-showcases-its-unique-approach-to-alzheimers-at-the-new-york-academy-of
https://www.nasdaq.com/press-release/annovis-bio-to-present-at-benzinga-global-small-cap-conference-on-december-8-2020
https://www.nasdaq.com/press-release/annovis-bio-to-present-at-the-new-york-academy-of-sciences-alzheimers-disease
https://www.nasdaq.com/press-release/annovis-bio-to-participate-in-a.g.p.s-virtual-healthcare-symposium-2020-11-16
https://www.nasdaq.com/press-release/annovis-bio-reports-positive-results-from-final-phase-of-%241.9m-nih-funded-chronic
https://www.nasdaq.com/press-release/annovis-bio-ceo-to-present-at-meridian-clinical-trials-summit-2020-11-02
https://www.nasdaq.com/press-release/annovis-bio-resumes-treatment-of-patients-in-ongoing-phase-2a-study-in-alzheimers
https://www.nasdaq.com/press-release/annovis-bio-ceo-receives-2020-smart-business-dealmaker-award-2020-10-22
https://www.nasdaq.com/press-release/annovis-bio-ceo-participates-in-roundtable-discussion-at-the-financial-times
https://www.nasdaq.com/press-release/annovis-bio-provides-third-quarter-2020-and-year-to-date-business-highlights-2020-10
https://www.nasdaq.com/press-release/annovis-bio-to-present-at-the-2020-bio-investor-forum-2020-10-12
https://www.nasdaq.com/press-release/annovis-bio-demonstrates-improved-axonal-transport-in-nerve-cells-and-brain-of-down
https://www.nasdaq.com/press-release/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-0
https://www.nasdaq.com/press-release/annovis-bio-begins-treatment-of-first-patients-in-its-phase-2a-alzheimers-and
https://www.nasdaq.com/press-release/ld-micro-360-companies-set-to-present-this-week-2020-08-31
https://www.nasdaq.com/press-release/annovis-bio-to-present-at-the-ld-500-virtual-conference-2020-08-25
https://www.nasdaq.com/press-release/annovis-bio-actively-recruiting-patients-for-its-phase-2a-trials-in-alzheimers-and
https://www.nasdaq.com/press-release/ld-micro-announces-preliminary-list-of-presenters-for-the-ld-500-2020-08-05
https://www.nasdaq.com/press-release/annovis-bio-ceo-appears-on-executive-leaders-radio-program-2020-07-23
https://www.nasdaq.com/press-release/annovis-bio-ceo-to-present-the-companys-novel-approach-to-treating-parkinsons-disease
https://www.nasdaq.com/press-release/annovis-bio-receives-institutional-review-board-approval-to-initiate-15-site-phase-2
https://www.nasdaq.com/press-release/annovis-bio-announces-positive-results-from-nih-funded-chronic-toxicology-study-2020
https://www.nasdaq.com/press-release/annovis-bio-to-present-at-the-june-2020-virtual-summer-investor-summit-2020-06-09
https://www.nasdaq.com/press-release/annovis-bio-issued-european-patent-for-method-of-treating-alzheimers-disease-with
https://www.nasdaq.com/press-release/annovis-bio-2020-annual-meeting-of-stockholders-to-be-held-on-june-3-2020-2020-06-01
https://www.nasdaq.com/press-release/annovis-bio-files-patent-application-for-method-of-inhibiting-preventing-or-treating
https://www.nasdaq.com/press-release/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report
https://www.nasdaq.com/press-release/annovis-bio-announces-plans-for-a-new-phase-ii-clinical-trial-to-treat-68-parkinsons
https://www.nasdaq.com/press-release/annovis-bio-publishes-results-of-alzheimers-and-parkinsons-animal-studies-2020-04-23
https://www.nasdaq.com/press-release/annovis-bio-to-hold-investor-webinar-and-qa-session-with-ceo-on-april-14-2020-04-13
https://www.nasdaq.com/press-release/annovis-bio-to-present-at-the-online-spring-investor-summit-on-march-25-2020-03-19
https://www.nasdaq.com/press-release/annovis-awarded-%241.7-million-nih-grant-for-anvs401-chronic-toxicology-studies-2020-02
https://www.nasdaq.com/press-release/annovis-issued-patent-for-method-of-treating-parkinsons-disease-and-other-lewy-body
https://www.nasdaq.com/press-release/annovis-bio-announces-update-on-phase-ii-clinical-trial-for-alzheimers-disease-2020
https://www.nasdaq.com/press-release/annovis-bio-announces-closing-of-initial-public-offering-and-full-exercise-of
